Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 13/20 | 0.34 |
| ▸ | F2 | P00734 | 7/20 | 0.34 |
| ▸ | PRSS1 | P07477 | 5/20 | 0.34 |
| ▸ | PRSS2 | P07478 | 4/20 | 0.32 |
| ▸ | PRSS3 | P35030 | 4/20 | 0.32 |
| ▸ | F9 | P00740 | 2/20 | 0.32 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.32 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.32 |
| ▸ | PLAT | P00750 | 2/20 | 0.31 |
| ▸ | PLG | P00747 | 1/20 | 0.31 |
| ▸ | F7 | P08709 | 1/20 | 0.31 |
| ▸ | PLAU | P00749 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5886032 | 0.99 | F10 (0.33) | F10F2PRSS1PRSS2PRSS3 | |
| SCHEMBL5886000 | 0.87 | GFER (0.35) | — | |
| SCHEMBL5885659 | 0.86 | F10 (0.38) | F10F2PRSS1ITGB3ITGA2B | |
| Hydrochloric Acid SCHEMBL5885398 | 0.85 | F10 (0.37) | F10F2PRSS1ITGB3ITGA2B | |
| SCHEMBL5885467 | 0.85 | F10 (0.36) | F10F2PRSS1PRSS2PRSS3 | |
| Hydrochloric Acid SCHEMBL5885592 | 0.84 | F10 (0.36) | F10F2PRSS1PRSS2PRSS3 | |
| SCHEMBL5885790 | 0.78 | F10 (0.39) | F10F2PRSS1ITGB3ITGA2B | |
| Hydrochloric Acid SCHEMBL5886028 | 0.78 | F10 (0.38) | F10F2PRSS1ITGB3ITGA2B | |
| SCHEMBL5885703 | 0.76 | ACACB (0.42) | F10F2PRSS1PRSS2PRSS3 | |
| Hydrochloric Acid SCHEMBL5885906 | 0.76 | ACACB (0.41) | F10F2PRSS1PRSS2PRSS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7005437-B2 | Substituted aryl and heteroaryl derivatives, the preparation thereof and the use therof as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2006-02-28 | — | — | US | claimed |
| US-20030045712-A1 | Substituted aryl and heteroaryl derivatives, the preparation thereof and the use therof as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-03-06 | — | — | US | claimed |
| US-7005437-B2 | Substituted aryl and heteroaryl derivatives, the preparation thereof and the use therof as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2006-02-28 | — | — | US | disclosed |
| US-20030045712-A1 | Substituted aryl and heteroaryl derivatives, the preparation thereof and the use therof as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030045712-A1 | Substituted aryl and heteroaryl derivatives, the preparation thereof and the use therof as pharmaceutical compositions | F2, F12, F3 | F10 16/4885F2 1/4885PRSS1 204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.